Subgenomic SARS-CoV-2 replicon and reporter replicon cell lines enable ultrahigh throughput antiviral screening and mechanistic studies with antivirals, viral mutations or host factors that affect COVID-19 replication
S. Lan, P. R. Tedbury, Y. T. Ong, R. Shah, R. L. Slack, M. E. Cilento, H. Zhang, H. Du, N. Lulkin, U. Q. Le, K. A. Kirby, I. Melcak, W. A. Cantara, E. A. Boggs, S. G. Sarafianos
This paper develops SARS-CoV-2 replicon systems and cell lines for antiviral screening and mechanistic studies, enabling research at lower biosafety levels.
bioRxiv · Dec 29, 2021 · PreprintMicrobiology